Maxcyte, Inc. MXCT
We take great care to ensure that the data presented and summarized in this overview for MAXCYTE, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MXCT
View all-
Cadian Capital Management, LP New York, NY8.19MShares$33.2 Million1.63% of portfolio
-
Black Rock Inc. New York, NY8.14MShares$33.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.78MShares$23.4 Million0.0% of portfolio
-
Vitruvian Partners LLP5.04MShares$20.5 Million7.62% of portfolio
-
Morgan Stanley New York, NY4.82MShares$19.6 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.19MShares$17 Million0.01% of portfolio
-
Mudita Advisors LLP London, X03.15MShares$12.8 Million6.94% of portfolio
-
Geode Capital Management, LLC Boston, MA2.47MShares$10 Million0.0% of portfolio
-
State Street Corp Boston, MA2.27MShares$9.21 Million0.0% of portfolio
-
River & Mercantile Asset Management LLP London, X02.06MShares$8.37 Million1.75% of portfolio
Latest Institutional Activity in MXCT
Top Purchases
Top Sells
About MXCT
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
Insider Transactions at MXCT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 09
2024
|
John Joseph Johnston |
SELL
Open market or private sale
|
Direct |
2,495
-1.73%
|
$7,485
$3.79 P/Share
|
|
Dec 09
2024
|
John Joseph Johnston |
BUY
Exercise of conversion of derivative security
|
Direct |
2,495
+0.58%
|
$4,990
$2.5 P/Share
|
|
Dec 06
2024
|
John Joseph Johnston |
SELL
Open market or private sale
|
Direct |
505
-0.35%
|
$1,515
$3.7 P/Share
|
|
Dec 06
2024
|
John Joseph Johnston |
BUY
Exercise of conversion of derivative security
|
Direct |
505
+0.35%
|
$1,010
$2.93 P/Share
|
|
Nov 01
2024
|
Stanley C Erck |
SELL
Open market or private sale
|
Direct |
47,689
-15.05%
|
$143,067
$3.72 P/Share
|
|
Nov 01
2024
|
Stanley C Erck |
BUY
Exercise of conversion of derivative security
|
Direct |
47,689
+13.08%
|
$0
$0.04 P/Share
|
|
Oct 28
2024
|
John Joseph Johnston |
SELL
Open market or private sale
|
Direct |
3,000
-2.07%
|
$9,000
$3.72 P/Share
|
|
Oct 28
2024
|
John Joseph Johnston |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+2.03%
|
$6,000
$2.93 P/Share
|
|
Oct 14
2024
|
Cynthia Collins |
BUY
Grant, award, or other acquisition
|
Direct |
51,679
+50.0%
|
-
|
|
Oct 02
2024
|
Stanley C Erck |
SELL
Open market or private sale
|
Direct |
21,607
-7.43%
|
$64,821
$3.71 P/Share
|
|
Oct 02
2024
|
Stanley C Erck |
BUY
Exercise of conversion of derivative security
|
Direct |
21,607
+6.92%
|
$0
$0.04 P/Share
|
|
Oct 01
2024
|
Stanley C Erck |
SELL
Open market or private sale
|
Direct |
26,082
-8.84%
|
$78,246
$3.78 P/Share
|
|
Oct 01
2024
|
Stanley C Erck |
BUY
Exercise of conversion of derivative security
|
Direct |
26,082
+8.12%
|
$0
$0.04 P/Share
|
|
Sep 26
2024
|
John Joseph Johnston |
SELL
Open market or private sale
|
Direct |
3,000
-2.07%
|
$9,000
$3.82 P/Share
|
|
Sep 26
2024
|
John Joseph Johnston |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+2.03%
|
$6,000
$2.93 P/Share
|
|
Sep 16
2024
|
Ali Soleymannezhad Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,400
+28.55%
|
-
|
|
Sep 04
2024
|
Stanley C Erck |
SELL
Open market or private sale
|
Direct |
29,767
-9.96%
|
$89,301
$3.97 P/Share
|
|
Sep 04
2024
|
Stanley C Erck |
BUY
Exercise of conversion of derivative security
|
Direct |
29,767
+9.06%
|
$0
$0.04 P/Share
|
|
Sep 03
2024
|
Stanley C Erck |
SELL
Open market or private sale
|
Direct |
17,922
-6.24%
|
$71,688
$4.1 P/Share
|
|
Sep 03
2024
|
Stanley C Erck |
BUY
Exercise of conversion of derivative security
|
Direct |
17,922
+5.88%
|
$0
$0.04 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 343K shares |
|---|---|
| Exercise of conversion of derivative security | 288K shares |
| Open market or private purchase | 100K shares |
| Open market or private sale | 288K shares |
|---|